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AbstrAct
Objective While disruptions in medications are common 
among patients who survive critical illness, there is limited 
information about specific medication-related problems 
among survivors of critical care. This study sought to 
determine the prevalence of specific medication-related 
problems detected in patients, seen after critical care 
discharge.
Design Consecutive patients attending an intensive care 
unit (ICU) follow-up programme were included in this 
single-centre service evaluation.
Setting Tertiary care regional centre in Scotland (UK).
Participants 47 patients reviewed after critical care 
discharge at an ICU follow-up programme.
Interventions Pharmacists conducted a full medication 
review, including: medicines reconciliation, assessing 
the appropriateness of each prescribed medication, 
identification of any medication-related problems and 
checking adherence.
Measurements Medication-related problems in patients 
following critical care discharge. Interventions and 
medication-related problems were systematically graded 
and risk factors were identified using an adapted version 
of the National Patient Safety Agency Risk Matrix.
Main results 69 medication-related problems were 
identified in 38 (81%) of the 47 patients. The most 
common documented problem was drug omission (29%). 
64% of the medication-related problems identified were 
classified as either moderate or major. The number of pain 
medications prescribed at discharge from intensive care 
was predictive of medication-related problems (OR 2.02, 
95% CI 1.14 to 4.26, p=0.03).
Conclusions Medication problems are common following 
critical care. Better communication of medication changes 
both to patients and their ongoing care providers may 
be beneficial following a critical care admission. In the 
absence of highly effective communication, a pharmacy 
intervention may contribute substantially to an intensive 
care rehabilitation or recovery programme.
InTroducTIon
Medication errors commonly occur in patients 
whose hospital stay includes an intensive care 
unit (ICU) admission.1 When patients are 
critically ill, their chronic drug therapies are 
frequently withheld in the ICU but are often, 
inappropriately, not restarted.2 3 Further-
more, new therapies are often commenced, 
which may be unnecessary in the long term, 
such as drugs prescribed for stress ulcer 
prophylaxis and antipsychotics prescribed 
for delirium.4 5 The care of the complex and 
dynamic physiology of these patients is made 
more challenging by frequent transitions in 
care across the healthcare system, and poor 
communication at the time of discharge.6 7
These medication problems may play a role 
in the development of Post Intensive Care 
Syndrome (PICS). PICS includes physical, 
social, cognitive and psychological problems 
for ICU survivors, in the months and years 
following hospital discharge.8–13 While risk 
factors for PICS are increasingly described, 
there have been few interventions to prevent 
PICS, and no interventions to treat PICS 
have demonstrated unequivocal positive 
benefits.14–20
While population-level data on ICU-asso-
ciated disruptions of some medications are 
available, few data are available to understand 
what specific problems ICU patients have 
with their medications after discharge home, 
and how consequential those might be. Only 
a single-centre study is available from the 
American health system; no data are avail-
able from integrated health systems such as 
the National Health Service.21 The purposes 
of this study, therefore, were to: determine 
specific medication-related problems among 
survivors of ICU; explore the changes made 
by a pharmacist in this context; and examine 
the potential risk factors for pharmacist-cor-
rectable medication errors.
MeThods
Consecutive patients enrolled in a post-ICU 
programme between September 2014 and 
June 2015 were evaluated by a pharmacist as 
a part of that programme. This evaluation 
focuses on a pharmacy intervention set in the 
post-ICU follow-up clinic.
Patients were drawn from a 20-bed mixed 
surgical/medical critical care unit in Glasgow 
Royal Infirmary (GRI). GRI is a tertiary 
referral centre for burns and pancreatic care. 
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Table 1 Intervention severity scale
Severity 1 2 3 4 5
Domains Negligible Minor Moderate Major Catastrophic
Clinical impact Not likely to be of 
clinical impact
Low risk to 
patient
Increased therapeutic 
benefit/avoidance of 
significant adverse 
effects
Prevent serious 
therapeutic failure/
avoidance of serious 
adverse effects
Life or organ-
threatening event
This pharmacy intervention was undertaken during a 
5-week programme for ICU patients and their caregivers. 
Intensive Care Syndrome: Promoting Independence and 
Return to Employment (InS:PIRE) is a multidisciplinary, 
peer-supported, rehabilitation programme. Participants 
of working age (18–64) were invited to take part between 
6 and 20 weeks after hospital discharge. However, there 
were some participants who had been discharged for 
longer (up to 3 years) who requested to take part in the 
programme. Caregivers were also encouraged to attend 
with patients. Patients were eligible for the InS:PIRE 
programme if they received mechanical ventilation for 
greater than 72 hours or had a high dependency unit 
stay of greater than 2 weeks. The InS:PIRE programme 
involved individual sessions for patients and their care-
givers with a pharmacist and physiotherapist along with 
interventions from medical, nursing, psychology and 
community services. A full description of the InS:PIRE 
intervention and the outcomes of this complex interven-
tion pilot have been published previously.22 23
The local Caldecott Guardian also reviewed the 
proposal (Clinical Governance structure within the UK). 
Data were collected between September 2014 and June 
2015. We used the Standards for Quality Improvement 
Reporting Excellence 2.0 to structure reporting (online 
supplementary material S1).24
Patient and public involvement
To ensure that this intervention was person centred and 
appropriate for the population, the team held a Patient 
and Family Advisory Council which fed directly into the 
programme. Ten to 12 patients and caregivers met every 2 
weeks for a year and coproduced the service with the staff 
involved in InS:PIRE. The Council looked at all aspects 
of the programme including the content and outcome 
measures used. All results of the study have been dissem-
inated to patients and caregivers during a patient and 
family day which was held within our ICU. If participants 
requested, written results were also available.
Measures
Pharmacy intervention
During the ICU follow-up programme (InS:PIRE) a 
full medication review was performed by the pharma-
cist. This included: medicines reconciliation, assessing 
the appropriateness of each of the prescribed medica-
tions, identification of any medication-related problems 
and checking adherence. The pharmacist recorded the 
patient’s prescribed medication prior to their admission 
to ICU, on discharge from ICU and at hospital discharge, 
and compared this with the medication prescribed when 
the patient attended InS:PIRE. Data for the above were 
available to the pharmacist from the hospital’s electronic 
healthcare system, primary care prescription information, 
patient, caregiver (if present) and community pharmacist 
if appropriate. All patients had medicines reconciliation 
performed within 24 hours of admission to the ICU; these 
data were also available to the pharmacist reviewing the 
patient. Patients were generally seen between week 1 and 
week 3 of InS:PIRE. However, if required, patients could 
be seen on more than one occasion (usually for safety 
reasons).
Medication-related problems which were identified 
during the pharmacy review were categorised according 
to the Hepler and Strand framework.25 This framework 
includes: clarification of any drug omissions, drug dose 
adjustment if necessary (according to disease severity, 
clinical guidelines and adverse effects), review of the 
duration of a drug treatment, new drug recommenda-
tions, education regarding a specific drug to enhance 
efficacy or improve safety, review of any incorrect or inef-
fective drugs prescribed and, lastly, an adverse drug reac-
tion report if appropriate.24 For the purpose of analysis, 
we categorised drugs according to the British National 
Formulary classification.26
All the interventions were classified by the primary 
pharmacist at the InS:PIRE clinic. This review was then 
externally validated by a senior pharmacist in the acute 
hospital setting. There were a small number of discrep-
ancies (n=4) regarding the potential significance of the 
interventions. These were discussed, and an outcome 
agreed between the two reviewers.
The significance of the interventions was classified on 
a severity scale of 1–5. This scoring system was adapted 
from the National Patient Safety Agency Risk Matrix.27 A 
score of 1 indicates an intervention that is not likely to be 
of clinically significant impact and a score of 5 indicates 
an intervention which could potentially prevent an organ 
or life-threatening event (table 1). Clinical examples of 
different levels of severity are reported in online supple-
mentary material S2.
Patients and their caregivers were asked if they were 
given enough information about their medication during 
their hospital stay and if they were made aware of the 
changes that had been made when they were discharged 
from hospital. They were also asked if they had any 
concerns about their medication. Finally, patients were 
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Table 2 Baseline demographics for patients who were 
reviewed by the pharmacist
Patient characteristic
Patients 
involved in 
the pharmacy 
intervention 
(n=47)
Gender (male %) 66
Age (years, median, IQR) 52 (44–57)
ICU LOS (days, median, IQR) 15 (9–26)
APACHE II (median, IQR) 23 (19–27)
Charlson Comorbidity Index (median, IQR) 1 (0–2)
SIMD decile (median, IQR) 3 (1–4)
Interventions received in ICU
  Mechanical ventilation (%) 94
  RRT (%) 34
  CVS (%) 47
APACHE II, Acute Physiology and Chronic Health Evaluation 
II; CVS, cardiovascular support (use of vasopressor therapy 
in the ICU); ICU LOS, intensive care unit length of stay; RRT, 
renal replacement therapy ; SIMD, Scottish Index of Multiple 
Deprivation.
asked if they would like a Medication Passport as a record 
of their current medication. Individualised, patient-held 
medication records have been used in specific patient 
groups, such as palliative care and diabetes, and have been 
shown to help support self-management, adherence, and 
improve communication surrounding the patient’s medi-
ation.28 29 The Medication Passport (http:// clahrc- northwest-
london. nihr. ac. uk/ resources/ mmp) which was designed by 
patients has been found to be a useful tool when initi-
ating conversations with healthcare professionals.30
Demographic measures
To understand comorbidities and their impact in this 
group, the Charlson Comorbidity Index, which is a 
method of categorising comorbidities of patients based 
on the International Classification of Diseases, was used.31
The Scottish Index of Multiple Deprivation (SIMD) 
is the Scottish Government’s tool for identifying those 
geographical areas in Scotland suffering from depriva-
tion. Within a research context, the SIMD data are split 
into quintiles, deciles or vintiles. For the purpose of this 
evaluation, deciles were used, with decile 1 being the 
most deprived and decile 10 being the most affluent.32
statistical analysis
We reported the total number of specific medication 
problems at different time points in the patient journey. 
Logistic regression using the statistical package R 
(V.3.3.0)33 was performed to determine if age, ICU length 
of stay, Acute Physiology and Chronic Health Evaluation 
II (APACHE II) score, requiring cardiovascular support, 
renal replacement therapy and number of medicines 
on admission or ICU discharge were associated with the 
number or severity of medication-related problems. We 
also examined the influence of comorbidities and depri-
vation on the number and severity of medication-related 
problems using the Charlson Comorbidity Index and the 
SIMD. Finally, as the most common drugs requiring an 
intervention were those associated with respiratory, cardi-
ovascular and pain medications, we examined whether 
being prescribed these classes of medication was predic-
tive of a medication-related problem or severity of the 
problem.
resulTs
Patients
Eighty-nine patients were invited to attend InS:PIRE, 49 
(55% of those invited) attended over the 1-year evalua-
tion. Forty-seven were reviewed by the pharmacist. The 
two patients who did not receive the pharmacy interven-
tion did not attend the week it was due. Baseline demo-
graphics for the patients who received the pharmacy 
intervention are shown in table 2. The median age of 
those who received the pharmacy intervention was 52 
years (IQR 43–57), with a median APACHE II score of 
23.19–27
Medications prescribed
The median number of pharmacy interventions per 
patient was 1 (IQR 1–2). The median number of drugs 
prescribed per patient before their ICU admission was 6 
(IQR 2–9). The median number of drugs prescribed per 
patient at ICU discharge was 6 (IQR 4–8); this increased 
to 7 (IQR 4–10) at hospital discharge. At the InS:PIRE 
clinic the median number of drugs each patient was 
prescribed had increased to 8 (IQR 5–11).
changes to medication
Of the 47 patients, 26 (55%) reported that they were not 
made aware of changes to their medication when they 
were discharged from hospital, 28 (60%) of patients had 
concerns about their medicines at their clinic visit and 34 
(49%) patients requested a Medication Passport.
Medication-related problems
Medication-related problems were identified in 38 (81%) 
of the 47 patients. Medication-related problems were iden-
tified with 69 (18.6%) of the medications patients were 
prescribed at the time of the pharmacy intervention. The 
most common documented problem was drug omissions 
accounting for 20 (29%) of the 69 identified (figure 1). 
This was followed by a suggested dosage adjustment on 13 
(19%) occasions then duration of treatment clarification 
12 (17%) times. The potential significance of these prob-
lems was classified by the InS:PIRE pharmacist. Forty-four 
(64%) of the medication-related problems were classi-
fied as severity score ≥3 (figure 2). The classes of drugs 
most commonly associated with requiring an intervention 
were cardiovascular 18 (26%), analgesic 15 (22%) and 
respiratory medicines 7 (10%). The medication-related 
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Figure 1 Incidence of medication-related problems.
Figure 2 Severity of medication-related problems.
Table 3 Logistic regression results
Model Variable OR (95% CI) P value
Medication-related problems
1 Gender (female) 0.51 (0.11 to 2.34) 0.38
2 Age 1.00 (0.93 to 1.08) 0.91
3 ICU LOS 1.01 (0.96 to 1.07) 0.79
4 APACHE II 1.01 (0.92 to 1.12) 0.8
5 Number of home 
medications (pre-ICU)
1.22 (0.99 to 1.57) 0.08
6 RRT 2.042 (0.42 to 
15.0)
0.41
7 CVS 3.90 (0.81 to 
28.44)
0.12
8 Number of medications 
on discharge from ICU
1.25 (0.95 to 1.72) 0.13
9 Number of analgesic 
medications on 
discharge from ICU
1.47 (0.75 to 3.77) 0.34
Significant medication-related problems (severity ≥3)
1 Gender (female) 0.59 (0.16 to 2.02) 0.40
2 Age 1.00 (0.95 to 1.06) 0.92
3 ICU LOS 0.99 (0.95 to 1.03) 0.54
4 APACHE II 1.04 (0.97 to 1.14) 0.30
5 Number of home 
medications (pre-ICU)
1.09 (0.94 to 1.27) 0.26
6 RRT 1.56 (0.47 to 5.42) 0.47
7 CVS 1.53 (0.48 to 4.93) 0.47
8 Number of medications 
on discharge from ICU
1.16 (0.94 to 1.45) 0.17
9 Number of analgesic 
medications on 
discharge from ICU
2.02 (1.14 to 4.26) 0.03
APACHE II, Acute Physiology and Chronic Health Evaluation 
II; CVS, cardiovascular support (use of vasopressor therapy in 
the ICU); ICU LOS, intensive care unit length of stay; RRT, renal 
replacement therapy; SIMD, Scottish Index of Multiple Deprivation.
problems identified by the pharmacists were also shared 
with the wider multidisciplinary team.
Predicting patients most at need
We predicted two sets of events: one examining if a 
patient had a medication-related problem, then second 
if a patient had a medication problem of severity ≥3 (clin-
ically significant). Patient demographics such as gender, 
age, ICU length of stay, APACHE II score, number of 
home medications prior to ICU admission, receiving 
renal replacement therapy or cardiovascular support, 
number of medications prescribed at ICU discharge and, 
more specifically, the number of cardiovascular, analgesic 
or respiratory medications prescribed at ICU discharge 
and none were significantly associated with the presence 
of any medication-related problem (table 3).
The only factor predictive of a clinically significant 
medication-related problem (severity ≥3; OR 2.02, 95% 
CI 1.14 to 4.26, p=0.03) was the number of pain medica-
tions prescribed at discharge from ICU (table 3).
dIscussIon
In this cohort study of consecutive patients seen in a 
post-ICU programme, medication-related problems 
following an ICU admission were common, occurring in 
81% of the patients studied. Of the interventions under-
taken, just under two-thirds were likely to improve thera-
peutic benefit or avoid serious side effects. The pharmacist 
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identified medication-related problems with 18.6% of the 
total medications reviewed at InS:PIRE. This is similar to 
the rate (16.1%) of medication-related problems identi-
fied in a recent UK study by pharmacists working within 
an ICU.34 We found the approach to identifying medica-
tion-related problems feasible and would recommend its 
adoption more widely in ICU follow-up clinics.
The most common medication-related problem found 
was omission of medicines for chronic disease states, 
which were withheld during the patient’s hospital stay 
and had not been restarted at their clinic review. This 
aligns with previous studies which have found that an ICU 
admission is associated with an increased risk of unin-
tentional discontinuation of long-term medications.1–3 
In one study, discontinuation of a statin or antiplatelet 
medication showed an increased risk of death, hospital 
admission and emergency department visit up to 1 year 
after hospital discharge.1 Medications commenced in 
ICU were also found to have been continued unneces-
sarily which is also consistent with previous studies.4 5
In this evaluation, 60% of patients reported they had 
concerns about their prescribed medication. Patient’s 
beliefs about their treatment influence their engagement 
and adherence with their management; concerns about 
their medicines can lead to intentional non-adherence 
and subsequent treatment failure.35 36 This is a modifi-
able problem. These concerns can be addressed; patients 
can be supported to make informed choices about their 
medicines using tools such as the Medication Passport. Such 
pharmacist engagement could improve mental health and 
emotional problems such as anxiety following critical care 
discharge for patients, by encouraging participants to be 
more engaged in their health.37 Given the challenges of 
resourcing such interventions in cost-restrained healthcare 
environment, the reduction in medication-related prob-
lems may help with long-term sustainable funding. More 
work is required to understand the overall impact of the 
intervention on patient safety and healthcare utilisation.
No single risk factor strongly differentiated patients 
who might benefit from a pharmacy intervention in this 
small study. However, it appears that patients who are on 
pain medications at ICU discharge are at particular risk 
of needing pharmacy input in the ICU recovery period. 
This risk factor is quite common, with chronic pain being 
reported in 44% of ICU survivors.38 Further work is needed 
to identify potential post-ICU clinic patients at greatest 
risk of medication-related problems, or conversely those 
who do not need the expertise of a pharmacist.
Strengths of this evaluation include its systematic 
approach to understanding pharmacy interventions and 
its rigour in categorising medication use, at all points in 
the patient journey. Limitations include that it was under-
taken in a single centre with a small sample of patients. 
More work is required across a number of centres to 
understand if this is a problem isolated from this partic-
ular centre. We did not have data on those patients who 
did not attend the ICU follow-up programme. It is not 
clear whether patients attended because of pharmacy 
issues, therefore, these findings may not be representa-
tive of the entire population. Finally, patients were also 
seen at a variety of time points after ICU, which may have 
influenced the reported findings.
conclusIon
Medication problems are common following critical 
care. This study demonstrated that the number of pain 
medications prescribed at discharge from intensive care 
was significantly predictive of medication-related prob-
lems. In the absence of highly effective communication, 
a pharmacy intervention may contribute substantially to 
an intensive care rehabilitation or recovery programme. 
A further multicentre study is required to test changes in 
longer term patient or system-centred outcomes.
Acknowledgements The authors thank all the patients involved in this evaluation 
and all staff in the InS:PIRE clinic.
Contributors Evaluation design: PM, CF, JM, TQ. Data collection: TQ, PM, RK, JM, 
HD. Data analysis: PM, JM, MS, TJI. Writing of article: all authors. Final review of 
article: all authors.
Funding PM, HD, TQ, JK, MD and JM were funded from the Health Foundation 
(UK) when undertaking this work. JM was funded by the CNO (Scotland). TJI's work 
was supported, in part, by the US Department of Veterans Affairs, Health Services 
Research and Development (IIR 13-079).
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This evaluation was undertaken as part of a service evaluation 
initiative within the ICU. Ethics approval was sought and waived by our hospital 
research and development department as this was deemed to be a quality 
improvement initiative. Data were collected between September 2014 and June 
2015.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Joanne McPeake http:// orcid. org/ 0000- 0001- 8206- 6801
references
 1 Bell CM, Brener SS, Gunraj N, et al. Association of ICU or hospital 
admission with unintentional discontinuation of medications for 
chronic diseases. JAMA 2011;306:840–7.
 2 Bell CM, Rahimi-Darabad P, Orner AI. Discontinuity of chronic 
medications in patients discharged from the intensive care unit. J 
Gen Intern Med 2006;21:937–41.
 3 Campbell AJ, Bloomfield R, Noble DW. An observational study of 
changes to long-term medication after admission to an intensive care 
unit. Anaesthesia 2006;61:1087–92.
 4 Pavlov A, Muravyev R, Amoateng-Adjepong Y, et al. Inappropriate 
discharge on bronchodilators and Acid-Blocking medications after 
ICU admission: importance of medication reconciliation. Respir Care 
2014;59:1524–9.
 5 Tomichek JE, Stollings JL, Pandharipande PP, et al. Antipsychotic 
prescribing patterns during and after critical illness: a prospective 
cohort study. Crit Care 2016;20.
 6 Eijsbroek H, Howell DCJ, Smith F, et al. Medication issues 
experienced by patients and carers after discharge from the intensive 
care unit. J Crit Care 2013;28:46–50.
 7 Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of 
adverse events affecting patients after discharge from the hospital. 
Ann Intern Med 2003;138:161–7.
Protected by copyright.
 o
n
 O
ctober 1, 2019 at University of G
lasgow.
http://bmjopenquality.bmj.com/
BM
J O
pen Qual: first published as 10.1136/bmjoq-2018-000580 on 27 September 2019. Downloaded from 
6 MacTavish P, et al. BMJ Open Quality 2019;8:e000580. doi:10.1136/bmjoq-2018-000580
Open access 
 8 Elliott DD, Harvey, MA JE, et al. Exploring the scope of post intensive 
care syndrome therapy and care: engagement of non-critical care 
providers and survivors in a second stakeholders meeting. Critical 
Care Medicine 2014;42:2518–26.
 9 Quasim T, Brown J, Kinsella J. Employment, social dependency 
and return to work after intensive care. Journal of the Intensive Care 
Society 2015;16:31–6.
 10 Wade DM, Howell DC, Weinman JA, et al. Investigating risk factors 
for psychological morbidity three months after intensive care: a 
prospective cohort study. Critical Care 2012;16.
 11 Iwashyna TJ, Ely EW, Smith DM, et al. Long-Term cognitive 
impairment and functional disability among survivors of severe 
sepsis. JAMA 2010;304:1787–94.
 12 McPeake J, Forrest E, Quasim T, et al. Health and social 
consequences of an alcohol-related admission to critical care: a 
qualitative study. BMJ Open 2016;6:e009944.
 13 Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years 
after acute respiratory distress syndrome. New England Journal of 
Medicine 2011;364:1293–304.
 14 Cuthbertson BH, Rattray J, Campbell MK, et al. The practical study 
of nurse led, intensive care follow-up programmes for improving 
long term outcomes from critical illness: a pragmatic randomised 
controlled trial. BMJ 2009;339:b3723.
 15 Walsh TS, Salisbury LG, Merriweather JL, et al. Increased hospital-
based physical rehabilitation and information provision after intensive 
care unit discharge: the recover randomized clinical trial. JAMA 
Intern Med 2015;175:901–10.
 16 Jones C, Backman C, Capuzzo M, et al. Intensive care diaries reduce 
new onset post traumatic stress disorder following critical illness: a 
randomised, controlled trial. Critical Care 2010;14:R168–78.
 17 Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired 
sedation and ventilator weaning protocol for mechanically ventilated 
patients in intensive care (awakening and breathing controlled trial): a 
randomised controlled trial. The Lancet 2008;371:126–34.
 18 Schaller SJ, Anstey M, Blobner M, et al. Early, goal-directed 
mobilisation in the surgical intensive care unit: a randomised 
controlled trial. The Lancet 2016;388:1377–88.
 19 Schofield-Robinson OJ, Lewis SR, Smith AF, et al. Follow-Up 
services for improving long-term outcomes in intensive care unit 
(ICU) survivors. Cochrane Database Syst Rev. 2018;11.
 20 Connolly B, Salisbury L, O'Neill B, O’Neill B, et al. Exercise 
rehabilitation following intensive care unit discharge for recovery from 
critical illness. Cochrane Database of Systematic Reviews 2015;113.
 21 Stollings JL, Bloom SL, Wang L, et al. Critical care pharmacists 
and medication management in an ICU recovery center. Ann 
Pharmacother 2018;52:713–23.
 22 McPeake J, Iwashyna TJ, Devine H, et al. Peer support to improve 
recovery following critical care discharge: a case-based discussion. 
Thorax 2017;72:856–8.
 23 McPeake J, Shaw M, Iwashyna TJ, et al. Intensive Care 
Syndrome: Promoting Independence and Return to Employment 
(InS:PIRE). Early evaluation of a complex intervention. PLoS One 
2017;12:e0188028.
 24 Hepler CD, Strand LM. Opportunities and responsibilities in 
pharmaceutical care. American Journal of Health-System Pharmacy 
1990;47:533–43.
 25 Goodman D, Ogrinc G, Davies L, et al. Explanation and elaboration 
of the Squire (standards for quality improvement reporting 
excellence) guidelines, V.2.0: examples of Squire elements in the 
healthcare improvement literature. BMJ Qual Saf 2016;25:e7.
 26 Joint Formulary Committee. British National formulary. 75th edn. 
London: BMJ Publishing and Royal Pharmaceutical Society of Great 
Britain, 2018.
 27 NPSA. A risk matrix for risk managers, 2008. Available: http://www. 
npsa. nhs. uk/ National
 28 Latimer EJ, Crabb MR, Roberts JG, et al. The patient care travelling 
record in palliative care: effectiveness and efficiency. J Pain 
Symptom Manage 1998;16:41–51.
 29 Dijkstra RF, Braspenning JCC, Huijsmans Z, et al. Introduction of 
diabetes passports involving both patients and professionals to 
improve hospital outpatient diabetes care. Diabetes Res Clin Pract 
2005;68:126–34.
 30 Barber S, Thakkar K, Marvin V, et al. Evaluation of my medication 
Passport: a patient-completed aide-memoire designed by patients, 
for patients, to help towards medicines optimisation. BMJ Open 
2014;4:e005608.
 31 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and 
validation. J Chronic Dis 1987;40:373–83.
 32 Scottish Government Scottish Index of multiple deprivation. A 
national statistics publication for Scotland. Edinburgh: Scottish 
Government, 2012.
 33 R Core Team. R: a language and environment for statistical 
computing. Vienna, Austria: R Foundation for Statistical Computing, 
2017. https://www. R- project. org/
 34 Shulman R, McKenzie CA, Landa J, et al. Pharmacist's review and 
outcomes: Treatment-enhancing contributions tallied, evaluated, and 
documented (PROTECTED-UK). J Crit Care 2015;30:808–13.
 35 Horne R, Chapman SCE, Parham R, et al. Understanding Patients’ 
Adherence-Related Beliefs about Medicines Prescribed for Long-
Term Conditions: A Meta-Analytic Review of the Necessity-Concerns 
Framework. PLoS One 2013;8:e80633 https:// doi. org/
 36 National Institute for Health and Clinical Excellence. Medicines 
adherence: involving patients in decisions about prescribed 
medicines and supporting adherence CG76. London: National 
Institute for Health and Clinical Excellence, 2009.
 37 Myhren H, Ekeberg O, Tøien K, et al. Posttraumatic stress, anxiety 
and depression symptoms in patients during the first year post 
intensive care unit discharge. Crit Care 2010;14.
 38 Battle CE, Lovett S, Hutchings H, et al. Chronic pain in survivors of 
critical illness: a retrospective analysis of incidence and risk factors. 
Critical Care 2013;17.
Protected by copyright.
 o
n
 O
ctober 1, 2019 at University of G
lasgow.
http://bmjopenquality.bmj.com/
BM
J O
pen Qual: first published as 10.1136/bmjoq-2018-000580 on 27 September 2019. Downloaded from 
